Schonfeld Strategic Advisors 13F: Adds $8.3M to ABBV Stake

Schonfeld Strategic Advisors significantly increased its investment in AbbVie Inc. (NYSE: ABBV) during the most recent reporting period. According to the firm's latest Form 13F filing with the Securities and Exchange Commission, the institutional investor added 32,932 shares of the drug manufacturer's stock. This transaction boosted its total position to 53,060 shares, which carried a market value of $13.4 million at the close of the quarter.

Schonfeld Shifts Capital into AbbVie

Schonfeld Strategic Advisors grew its position in AbbVie by 163.61%, moving from a previous holding of 20,128 shares to its current 53,060 shares. As a multi-strategy hedge fund, Schonfeld typically employs quantitative and tactical trading models to manage its portfolio. This rapid expansion of its AbbVie stake represents a notable allocation of capital toward the large-cap healthcare company, suggesting the fund's tactical models found favorable setups in the stock.

AbbVie Stock Price Performance

On Saturday, AbbVie shares were valued at $252.59. The stock has been trading in a 52-week range of $190.75 to $267.47. It is currently positioned above its 200-day moving average of $229.80, though it sits slightly below its 50-day moving average of $255.68. With a beta of 0.281, the stock has historically shown much less volatility than the broader market.

Recent Earnings

AbbVie reported annual revenue of $64.39 billion, representing a revenue growth rate of 10.2%. The company's net margin stands at 9.8% with a return on equity of 36.3%. AbbVie posted earnings per share of $3.54. While the trailing P/E ratio is high at 74.71, the forward P/E ratio is lower at 16.26, showing that analysts expect earnings to improve. The company's next earnings report is scheduled for October 29, 2026.

Dividend

AbbVie continues to distribute cash to its shareholders, paying an annual dividend of $6.92 per share. This payment provides investors with a dividend yield of 2.62% based on current trading levels. The company's payout ratio is 1.90, meaning its current dividend payout exceeds its trailing net income, a common metric for income-focused investors to monitor.

Analysts Set New Price Targets

Wall Street researchers have kept a close eye on the pharmaceutical company. On October 13, 2026, RBC Capital reiterated its Outperform rating with a price target of $280.00. On October 9, 2026, UBS kept a Neutral rating on the stock while lifting its price target to $275.00, and Guggenheim reiterated its Buy rating with a $288.00 price target. On October 8, 2026, JP Morgan maintained an Overweight rating with a price target of $300.00, and Cantor Fitzgerald kept its Overweight rating with a $290.00 target. Morgan Stanley maintained its Overweight rating with a $310.00 target on October 7, 2026. Earlier in the month, Scotiabank maintained a Sector Outperform rating with a $320.00 target on October 6, 2026. On September 10, 2026, HSBC maintained a Buy rating with a $315.00 price target. Out of 28 analyst opinions, the stock has a consensus buy rating and a mean target price of $278.61.

About AbbVie

AbbVie is a major biopharmaceutical developer based in North Chicago, Illinois. The company designs, manufactures, and markets specialty medicines worldwide. Its portfolio includes widely recognized treatments such as Skyrizi and Rinvoq for autoimmune disorders, oncology treatments like Imbruvica and Venclexta, and popular aesthetic products including Botox Cosmetic and the Juvederm collection.

Looking Forward

Investors interested in AbbVie should watch for its upcoming earnings announcement on October 29, 2026, to see if the company's financial results match Wall Street's expectations. Please note that Form 13F filings are backward-looking reports that show holdings from the end of a previous quarter, so Schonfeld's actual portfolio may have changed since the document was filed.